NASDAQ$DERM
Journey Medical Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported a decrease in revenue due to generic competition of Targadox, and are progressing with DFD-29 clinical trials.
Journey Medical reported a decrease in revenue for Q3 2022 compared to Q3 2021, primarily due to generic competition of Targadox. However, the company is progressing with its DFD-29 Phase 3 clinical program and anticipates top-line data in the first half of 2023.
- Revenue for Q3 2022 was $16.1 million, compared to $19.6 million for Q3 2021.
- The decline in revenue was primarily attributed to generic competition of Targadox and an increase in net revenue of Accutane.
- 75% enrollment achieved in DFD-29 Phase 3 clinical program for papulopustular rosacea.
- Top-line data from the DFD-29 Phase 3 clinical program is anticipated in the first half of 2023.
Headline financials
Revenue & EPS history
Journey Medical · Revenue · Quarterly
$16.1M
Forward guidance
Journey Medical expects to report record revenue for the full year 2022 and anticipates DFD-29 will achieve peak annual net sales exceeding $100 million after approval.
Tailwinds
- Expect to report record revenue for the full year 2022.
- Anticipate announcing top-line data from the DFD-29 trials in the first half of 2023.
- Expect to file a New Drug Application in the second half of 2023.
- Anticipate that DFD-29 will achieve peak annual net sales exceeding $100 million.
- Plan to launch another product in the upcoming months.
Headwinds
- Sales revenue for Q3 2022 continues to be negatively impacted primarily by the effect of Targadox generic competition versus Q3 2021.
- Cybersecurity breach in September 2021 resulted in losses of $9.5 million.
- The process to recover funds from the cybersecurity breach could take as long as 6 months or more to complete.
- Uncertainties relating to preclinical and clinical testing.
- Risks relating to the timing of starting and completing clinical trials, including disruptions that may result from hostilities in Europe.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
-2.9%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+5.1%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+22.0%
Q1 2025
Best reaction
-26.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -26.8% | -1.1% | — | |
| Q1 2026 | +3.0% | +24.4% | +26.5% | |
| Q3 2025 | -15.3% | -12.4% | -15.5% | |
| Q2 2025 | -15.1% | -18.0% | -16.7% | |
| Q1 2025 | +22.0% | +15.2% | +13.6% | |
| Q4 2024 | -3.6% | -2.8% | +21.7% | |
| Q3 2024 | -8.2% | -7.5% | -9.3% | |
| Q2 2024 | -3.2% | -11.0% | -3.8% | |
| Q1 2024 | +2.8% | -1.7% | +69.2% | |
| Q4 2023 | -14.1% | -3.9% | -9.4% | |
| Q3 2023 | +15.7% | +14.8% | +105.5% | |
| Q2 2023 | +14.0% | +4.7% | +21.5% | |
| Q1 2023 | -10.1% | -23.2% | +44.9% | |
| Q4 2022 | +3.1% | +13.1% | +26.3% | |
| Q3 2022 | -8.7% | -9.2% | -27.2% | |
| Q2 2021 | -4.3% | -7.0% | -30.1% | |
| Q2 2022 | -4.3% | -7.0% | -30.1% | |
| Q1 2022 | -12.3% | +5.1% | +0.8% | |
| Q1 2021 | -12.3% | +5.1% | +0.8% | |
| Q4 2021 | +5.4% | +6.1% | -1.8% | |
| Q3 2020 | +3.4% | -0.1% | -24.3% | |
| Q4 2020 | +3.4% | -0.1% | -24.3% | |
| Q3 2021 | +0.0% | +0.0% | -25.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro